Entrada reports positive Phase 1 data for ENTR-601-44; plans Phase 2 trials in Q4 2024

Entrada Therapeutics, Inc.

No serious or drug-related adverse events; ENTR-601-44 well-tolerated across all 4 dose cohorts (0.75-6 mg/kg) in 32 healthy volunteers.
At 6 mg/kg, mean exon skipping 0.44% (range 0.3-0.65%), statistically significant vs placebo (p<0.005); muscle concentration mean 53.8 ng/g.
Plans to submit regulatory applications in Q4 2024 for Phase 2 trials of ENTR-601-44 (exon 44) and ENTR-601-45 (exon 45).
ENTR-601-50 Phase 2 trial filing expected in 2025; company sees potential for dosing intervals of at least six weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.